(c) and (d) A committee headed by Dr. I. Z. Bhatti was appointed to study the pattern of Trade margins in Pharmaceuticals Industry, whose final report is awaited.

Cost study of diclofenac Sodium by BICP

645. SHRI RAJNI RANJAN SAHU: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 401 given in the Rajya Sabha on the 18th July, 1991 and state:

(a) when did Government ask BICP to conduct cost study of the Diclofenac Sodium;

(b) whether it is a fact that BICP has not so far studied costing of this drug; and

(c) if so, what action has been taken by Government and by when Government would fix the price of the drug?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) The Government asked the BICP to conduct cost study of Diclofenac Sodium in October 1990.

(b) The report of BICP on cost-cum-technical study of this bulk drug has not been received by this Department till date.

(c) After getting the recommendation of BICP, the fair price of this bulk drug would be worked out and notified.

Reference of cases of drugs to directorate of revenue intelligence

664. SHRIMATI SATYA BAHIN:
SHRI H. HANUMANTHAPPA:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 755 given in the Rajya Sabha on 25th July, 1991 and state:

(a) when each case of each company was referred to the Directorate of Revenue Intelligence;

(b) what action has been taken so far on this issue;

(c) how many complaints were received by Government alleging over invoicing and how many cases of overinvoicing has been detected durng the current year;

(d) whether it is a fact that instances of falsification of balance sheets by the producers of Sulphamethoxazole, Ethambutol, Trimethoprim and Cephalexin have come to the notice of Government; and

(e) if so, the details thereof and action taken on each?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (e) The details of complaints of instances over-invoicing were given in reply to Rajya Sabha Unstarred Question No. 1664 answered on 1-8-91. These complaints were forwarded to the Directorate of Revenue Intelligence for further investigation. Action would be taken after receiving findings from the Directorate of Revenue Intelligence.

Adjournment of M/s Glaxo's case

647. SHRI MODH. KHALEELUR RAHMAN:
SHRI ASHOK NATH VERMA:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 375 given in the Rajya Sabha on the 18th July, 1991 and state:

(a) whether it is a fact that Government sought adjournment many times in M/s. Glaxo's case;

(b) if so, how many times and on what ground adjournment was sought and how many times the company took adjournment;

(c) when did the company file writ petition and on what grounds and what is the progress;

(d) what are the grounds on which Delhi High Court gave interim stay and what steps have been taken by Government to get the stay vacated;

(e) whether Government have moved the Supreme Court against the decision of Delhi High Court; and

(f) if so, when and what is the outcome and if not, the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (f) The Writ Petition was filed by M/s. Glaxo in the Delhi High Court 21-7-90 against the Govt's Notice dated 18-6-1990 conveying the tentative liability of the Company as Rs. 66.35 crores. Since then, adjournments have taken place on account of various reasons which generally become unavoidable in a litigation, like for enabing the company to amend its Writ Petition in view of the Govt. having increased the tentative liability to Rs. 71.21 crores on 16-11-90, to enable the parties to file counter-affidavits and replies thereto, before and after the said amendment, non-availability of Counsels etc. The case will be defended in the best public interest in accordance with the advice of Govt's legal experts.

Furnishing of details by M/s Hoechst

648. SHRI MOHD. KHALEELUR RAHMAN:

SHRI ASHOK NATH VERMA:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 375 given in the Rajya Sabha on the 18th July, 1991 and state:

(a) whether it is a fact that M/s Hoechst did not follow the time schedule and the decision of Bombay High Court in providing the details required by Government;

(b) if so, what steps have been taken by Government in this direction;

(c) whether it is a fact that Government have been asking M/s Hoechst to provide details for the last so many years;

(d) if so, when it was asked for the first time and how many reminders were sent; and

(e) what action Government are proposing to take under these circumstances?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (e) As envisaged in the Bombay High Court's order dated the 8th March, 1991, M/s Hoechst did make available some information and data before the expiry of 8 weeks' period stipulated in the said order. It was, however, noticed that the information supplied by the company did not tally with the one made available by it in 1987-88 to the Special Team and therefore it needed reconciliation, and the same is being done. The case will be processed in accordance with the provisions of the DPCOs and the directions of the Courts.

Imoprt Bill of M/s German Remedies

649. SHRI MOHD. KHALEELUR RAHMAN:

SHRI ASHOK NATH VERMA:

Will the PRIME MINISTER be pleased to refer to the answer to unstarred Question 374 given in the Rajya Sabha on the 18th July, 1991 and state:

(a) whether it is a fact that import bill of M/s German Remedies which was Rs. 3.67 crores at CIF cost during the year 1987 jumped to Rs. 20 crores during 1990-91;

(b) what are the reasons for such increase at a time when country is facing foreign exchange problem;

(c) whether it is a fact that company is required to provide imports break up under drug Policy, 1986 and DPCO, 1987;

(d) if so, the details provided by the company; and

(e) when the matter of over invoicing was referred to Finance Ministry and what is the present status?